Many Georgians are hesitant to get the vaccine, and the pace of vaccinations has slowed recently. Roughly 50% of Georgia adults have received at least one dose of the vaccine as of last week, well below the national average of 64%. At the current rate, Georgia will not reach 70% of adult vaccinations — a nationwide goal the Biden administration hoped to achieve by July 4, an Atlanta Journal-Constitution analysis shows.
Additionally, only eight states have a lower vaccination rate than Georgia among those 12 and older per 100,000 residents, according to federal data. The U.S. Food and Drug Administration last month authorized the use of the Pfizer-BioNTech vaccine in adolescents ages 12 to 15. But few in that age group have been vaccinated in many parts of the state.
As of last week, about 15 people agreed to participate in the study at Emory, which began about two weeks ago. Researchers are looking for 400 participants nationwide. Similar studies are being conducted at 10 other sites in Maryland, New York, Ohio, Pennsylvania, Texas and Washington state.
Emory University is participating in a COVID-19 vaccine booster study. The university created this flyer to recruit participants. (Courtesy of Emory University)
Moderna released a report last month that found a single dose of its vaccine was successful in fighting variants first identified in Brazil and South Africa. Cases of both those variants, among others, have been reported in Georgia.
Researchers will study two groups. The first are adults 18 and older who received any of the three vaccines approved for emergency use in the United States. They will receive a booster shot three to five months after their last vaccine shot. The second group are people who haven’t been vaccinated. They will receive two doses of the Moderna vaccine and eventually a booster shot.
People who’ve had COVID-19 are ineligible for the study because they have developed antibodies that make the booster research ineffective, Edupuganti explained.
Dr. Anthony Fauci, the federal government’s point person on the COVID-19 pandemic response, has suggested a booster shot will be needed.
“I think we will almost certainly require a booster sometime within a year or so after getting the primary (shot) because the durability of protection against coronaviruses is generally not lifelong,” Fauci, director of the National Institute of Allergy and Infectious Diseases, said during an event hosted by the news site Axios last month.
Fauci couched his comments later that week in a CBS interview.
“We don’t know whether we will have to do it and when we will have to do it,” he said. “There’s estimates ... The fact is we don’t know. But it would really be foolish not to plan for the possibility that we might have to boost people.”
David Wyse, 70, a retired information technology worker who lives in Decatur, volunteered for the study and received his first shot last week. Wyse said he’s had no serious side effects. The Emory team hopes to have some initial findings by early fall.
David Wyse, 70, of Decatur is participating in a COVID-19 vaccine booster trial at Emory University. (Contributed)
Wyse has participated in other Emory research and felt it was important to sign up for the research to determine if the additional shot will provide the necessary antibodies. He received two Moderna vaccine shots, the first in January and the second in February.
“Science matters,” Wyse said. “I think research is good and it’s important to know how things work and that the vaccine works and they’re safe through things like this.”
And so while many Georgians have not received their first vaccine shot, Wyse has now had three.
“It’s my superpower now, I guess,” Wyse said with a laugh.
Booster shot study
Emory University is looking for people to participate in its COVID-19 vaccine booster shot study. For more information, call 404-712-1371 or email vaccine@emory.edu.
The Link LonkJune 15, 2021 at 05:52PM
https://ift.tt/3gCs8X9
Emory University partners on COVID-19 vaccine booster shot study - Atlanta Journal Constitution
https://ift.tt/2DVP6sH
No comments:
Post a Comment